A carregar...
Personalized treatment in advanced ALK-positive non-small cell lung cancer: from bench to clinical practice
The discovery of anaplastic lymphoma kinase (ALK) gene rearrangements and the development of tyrosine kinase inhibitors (TKI) that target them have achieved unprecedented success in the management of patients with ALK-positive non-small cell lung cancer (NSCLC). Despite the high efficacy of crizotin...
Na minha lista:
| Publicado no: | Onco Targets Ther |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5074703/ https://ncbi.nlm.nih.gov/pubmed/27799783 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S98347 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|